Outlook Therapeutics Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Outlook Therapeutics stock has a consensus rating of "Buy" and an average price target of $5.50. The average 1-year stock price forecast is 200.55% higher than the current stock price, while the lowest is $0.50 (-72.68%) and the highest is $10 (+446.45%).

Price Target: $5.50 (+200.55%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$0.50	$5.50	$6.00	$10
Change	-72.68%	+200.55%	+227.87%	+446.45%

* Price targets were last updated on Apr 8, 2026.

Analyst Ratings

The average analyst rating for Outlook Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	2	2	1	1	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	3	3	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Julian Harrison BTIG	BTIG	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	May 18, 2026
Douglas Tsao H.C. Wainwright	H.C. Wainwright	Hold Reiterates $0.5	Hold	Reiterates	$0.5	-72.68%	Apr 8, 2026
Edward Woo Ascendiant	Ascendiant	Buy Maintains $10 → $6	Buy	Maintains	$10 → $6	+227.87%	Mar 11, 2026
Daniil Gataulin Chardan Capital	Chardan Capital	Hold Maintains $3 → $1	Hold	Maintains	$3 → $1	-45.36%	Jan 2, 2026

Financial Forecast

Revenue This Year

1.20M

from 1.41M

-15.11%

from 1.41M

Revenue Next Year

45.73M

from 1.20M

3,710.63%

from 1.20M

EPS This Year

-0.51

from -1.89

EPS Next Year

-0.22

from -0.51

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Sep 30, 2021	Sep 30, 2022	Sep 30, 2023	Sep 30, 2024	Sep 30, 2025	Sep 30, 2026
Revenue	-	-	-	-	1.41M	1.20M
Revenue Growth	-	-	-	-	-	-15.11%
Gross Profit	-38.96M	-42.33M	-26.45M	-	57.21K	540.00K
Gross Margin	-	-	-	-	4.05%	45.00%
Operating Income	-51.73M	-63.07M	-53.13M	-71.70M	-67.06M	-51.00M
Net Income	-53.16M	-66.05M	-58.98M	-75.37M	-62.42M	-53.44M
EPS	-	-	-	-	-1.89	-0.51
Free Cash Flow	-35.62M	-32.53M	-24.26M	-44.30M	-27.15M	-85.00M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	2.0M
Avg	1.2M
Low	400,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	41.5%
Avg	-15.1%
Low	-71.7%

EPS Forecast

EPS	2026	2027	2028
High	-0.51
Avg	-0.51
Low	-0.51

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-